博瑞医药: 2024年年度利润分配方案公告

Core Viewpoint - The company plans to distribute a cash dividend of 0.096 CNY per share, amounting to a total of approximately 40.52 million CNY, which represents 21.42% of the net profit attributable to shareholders for the year [1][2][3] Profit Distribution Plan - The profit distribution is based on the total share capital registered on the equity distribution record date, with a proposed cash dividend of 0.96 CNY for every 10 shares held [1][2] - The total number of shares eligible for distribution is 422,106,055, after excluding 363,461 shares held in the company's repurchase account [1][2] - The cash dividend distribution plan is subject to approval at the company's 2024 annual general meeting [2][8] Financial Performance - For the reporting period, the company achieved a revenue of 1.28 billion CNY, reflecting an 8.74% year-on-year increase [4] - The net profit attributable to shareholders was approximately 189.17 million CNY, a decrease of 6.57% compared to the previous year [4][5] - The company’s cumulative undistributed profits as of December 31, 2024, amounted to 561.12 million CNY [1][3] R&D Investment - The company has increased its R&D investment to approximately 311.79 million CNY, a 25.42% increase year-on-year, representing 24.31% of its revenue [5][6] - The R&D investment for innovative drugs and inhalation formulations accounted for 62.78% of total R&D spending, with significant year-on-year growth [6][7] Business Strategy and Development - The company focuses on high-tech pharmaceutical manufacturing, emphasizing innovation in generic drugs, complex formulations, and original new drugs [4][5] - The company is in a critical growth phase, requiring substantial funding for R&D and operational needs, which will be supported by retained earnings and other financing channels [4][6] Shareholder Engagement - The company has implemented measures to facilitate shareholder participation in the cash dividend decision-making process, including in-person and online voting options for the annual general meeting [6][7]